ANI Pharmaceuticals
ANIP
32 hedge funds and large institutions have $25.8M invested in ANI Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 4 closing their positions.
960% more call options, than puts
Call options by funds: $9.26M | Put options by funds: $873K
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
144% more capital invested
Capital invested by funds: $10.6M → $25.8M (+$15.2M)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
14% more funds holding
Funds holding: 28 → 32 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MOACM
Mutual of America Capital Management
New York
|
+$1.19M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$998K |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$357K |
| 4 |
Morgan Stanley
New York
|
+$328K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$266K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$890K |
| 2 |
ICOA
Investment Centers of America
Bismarck,
North Dakota
|
-$189K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$4.62K |
| 4 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$4K |
| 5 |
Barclays
London,
United Kingdom
|
-$207 |
ANIP Hedge Fund Activity: Q4 2013 in Review
32 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2013, worth a combined $25.8M — up 144% from $10.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ANIP positions and 4 closed out — a net gain of 4 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Mutual of America Capital Management, adding an estimated $1.19M. The largest seller was Healthcare Value Capital, cutting an estimated $890K.
- 32 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2013, up from 28 in Q3 2013.
- Funds reported $25.8M of ANI Pharmaceuticals stock for Q4 2013, up 144% quarter-over-quarter.
- 8 funds opened new ANI Pharmaceuticals positions in Q4 2013 and 4 closed out, a net change of +4 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2013 was Mutual of America Capital Management, an estimated $1.19M added.
- The largest ANI Pharmaceuticals seller in Q4 2013 was Healthcare Value Capital, an estimated $890K sold.
Based on aggregated 13F filings for Q4 2013.